Sector News

Medtronic-Covidien merger imminent after Irish court’s OK

January 26, 2015
Life sciences
The Irish High Court has approved the $43 billion merger between Medtronic Inc. and Ireland’s Covidien, clearing the way for the deal to close later today.
 
Medtronic and Covidien announced the court’s decision this morning. They will combine in a new company called Medtronic plc that’s legally based in Dublin, though its management remains at Medtronic’s current headquarters in Fridley, Minn. The two companies’ shares will continue to trade normally today, with the new stock starting to trade Tuesday.
 
Shareholders of the two companies approved the deal earlier this month.
 
The medical-device giant announced in June it would buy Dublin-based medical-products manufacturer Covidien.
 
By Mark Reilly
 

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]